Abstract a-Dystroglycanopathies are a group of muscular dystrophies characterized by a-DG hypoglycosylation and reduced extracellular ligand-binding affinity. Among other genes involved in the a-DG glycosylation process, fukutin related protein (FKRP) gene mutations generate a wide range of pathologies from mild limb girdle muscular dystrophy 2I (LGMD2I), severe congenital muscular dystrophy 1C (MDC1C), to Walker-Warburg Syndrome and Muscle-Eye-Brain disease. FKRP gene encodes for a glycosyltransferase that in vivo transfers a ribitol phosphate group from a CDP -ribitol present in muscles to a-DG, while in vitro it can be secreted as monomer of 60kDa. Consistently, new evidences reported glycosyltransferases in the blood, freely circulating or wrapped within vesicles. Although the physiological function of blood stream glycosyltransferases remains unclear, they are likely released from blood borne or distant cells. Thus, we hypothesized that freely or wrapped FKRP might circulate as an extracellular glycosyltransferase, able to exert a "glycan remodelling" process, even at distal compartments. Interestingly, we firstly demonstrated a successful transduction of MDC1C FKRP protein boosted by exosomes determined its restoration within muscle tissues, an overall recovery of a-DG glycosylation and improved muscle strength, suggesting a systemic supply of FKRP protein acting as glycosyltransferase.
Introduction
The congenital muscular dystrophies (CMDs) are a group of clinically heterogeneous infantile autosomal disorders, typically characterized by dystrophic symptoms such as skeletal muscle weakness and contractures, marked psychomotor developmental delays, and cardiac and neurological defects. In addition to the well-known CMDs dependent on dystrophin mutations (1), a-Dystroglycanopathy is a newly emerging subgroup determined by gene mutations associated to a defective a-Dystroglycan (a-DG) glycosylation. The glycoprotein a-DG is placed on the peripheral membrane of muscle tissues, and it is characterized by a peculiar O-mannose -linked glycan structure that exerts a key role in binding the internal actin cytoskeleton of muscle fibers to the protein ligands of the extracellular matrix basal lamina (i.e. laminin, agrin, and perlecan). Therefore, defects in a-DG glycosylation lead to impaired cell membrane integrity, loss of structural stability, fiber damage and continuous regeneration/degeneration cycles. The proper a-DG-extracellular matrix (ECM) ligand binding function is strictly regulated by the unique structure and the complex glycosylation of all the sugar moieties composing the a-DG (2), thus suggesting the existence of several autosomal recessive mutations in genes directly involved into glycosylation modifications. Among the most known mutated genes, Protein-O-mannosyl transferase 1 (POMT1) and Protein-O-mannosyl transferase 2 (POMT2), catalyse the initial O-mannosylation of a-DG (3); LARGE acts as a bifunctional glycosyltransferase of xylose and glucuronic acid (4) . Fukutin-related protein (FKRP) is implicated in post-phosphoryl modification of a-DG (5) and underlies both the severe congenital muscular dystrophy type 1 (MDC1C) and the mild limb girdle muscular dystrophy type 2I (LGMD2I), two forms of dystrophy associated with a wide spectrum of clinical severity (6) . In particular, it has been recently published that FKRP acts in tandem with Fukutin as transferase of ribitol 5-phosphate (Rbo5P), transferring a ribitol phosphate group from CDP-ribitol, a rare sugar unit presented in muscle to a-DG (7). Although CDP-ribitol clearly represents a donor substrate for FKRP, the precise sequence of action leading to CDP-ribitol transportation to the Golgi, as well as the exact site where ribitol phosphate groups are incorporated into O-mannose glycan structure, is still poorly described (8) . Moreover, the relegation of glycosyltransferases within the ER-Golgi apparatus belongs to a glycosylation concept that has been recently out-dated, thanks to the identification of blood derived circulating glycosyltransferases that can affect glycans on distant cells and extracellular environment (9) . In this new scenario, we hypothesized that FKRP might circulate as an extracellular glycosyltransferase, able to modify distal glycan structures. Interestingly, we employed a lentiviral vector expressing the wild-type of human FKRP gene to demonstrate the feasibility of transducing both dystrophic blood derived CD133þ cells, isolated from a MDC1C patient with FKRP gene alterations, and satellite cells derived from FKRP L276I KI mouse model (10) .
Moreover, we showed that FKRP transduced cells were driven to release exosomes carrying FKRP. Similarly, we observed the presence of blood freely circulating FKRP carried by exosomes isolated from plasma of FKRP L276I KI mice intramuscularly injected with ex vivo-engineered satellite cells. Furthermore, we performed exosome tracking in vitro exploiting a microfluidic bioreactor to reproduce in vivo kinetics, timing of distribution and fusion to targeted tissues. The dual distribution of FKRP protein determined its expression restoration within muscle tissues, an overall recovery of a-DG glycosylation, and improved muscle strength, suggesting a systemic supply of FKRP protein acting as glycosyltransferase.
Results

FKRP expression in transduced human MDC1C
CD133þ blood-derived stem cells and murine FKRP L276I KI satellite cells
Human MDC1C CD133þ blood-derived stem cells. Following cells isolation through magnetic columns, CD133þ cells were immediately cultured in vitro; culture maintenance did not affect morphology of cells that remained round in shape and uniform in size immediately after the isolation (Fig. 1A) , as well as after 2 weeks in culture ( . These data were summarized in the histogram graph in Figure 1D '''. Since MOI of 20 presented the best outcomes in terms of transduction efficacy ( Fig. 1D '' and D'''), we proceeded to infect MDC1C blood-derived CD133þ stem cells with lentiviral MOI 20. Trypan blue exclusion assay performed on LV-FKRP CD133þ stem cells infected with this MOI did not display detrimental effects on cell proliferation, for all the experimental time points. MOI 20 transduced FKRP CD133þ stem cell proliferation curve resembled the characteristic curve of not infected CD133þ blood-derived stem cells, with an initial decrease of cell viability and a peak between 15 and 20 days (Fig. 1E ). WB analysis performed 7 days after infection confirmed the restoration of lentivirus mediated wild type fukutin related protein expression in the engineered human MDC1C blood-derived CD133þ stem cells (Fig. 1F, Fig. 2A) and 80.3% of Pax7þ cells co-expressed CD29 marker ( Fig. 2A') . SCs morphology and expression of specific myogenic markers were evaluated at different time-points after culturing cells in myogenic differentiation medium ( Fig. 2E-G ; Supplementary Material, Fig. S1 ). Before the supplementation of serum starvation medium (T0), SCs showed the maintenance of Pax7 (in red in Fig. 2E ) and desmin (in green in Fig. 2E ) expression, while at T7 they started to elongate and form small Pax7-desminþ myotubes (Fig. 2F ) that increased in number and size after 14 days (T14) (Fig. 2G) . We determined which pLenti-CAG (hFKRP)-Rsv (GFP-Puro) MOI was most effective in transducing 30,000 events. 97,6% cells were PAX7þ (A), 80,3% of PAX7þ cells co-expressed CD29 marker (A'). Cells morphology was evaluated by bright field microscopy at different time-points: immediately after cells seeding (T0) (B), after 7 days (T7) (C) and 14 days (T14) (D) in myogenic differentiation medium (serum starvation condition).
Immunofluorescent analysis was performed to evaluate specific myogenic satellite markers expression. At T0, satellite clones were positive for a-desmin (in green) and Pax7 (in red) (E). At T7 cells lost the expression of the early myogenic marker Pax7, and maintained the expression of a-desmin; a -desmin staining highlighted the presence of a few myotubes (F). At T14, cells were still positive for a-desmin and were finally fused to form myotubes (G). Images were captured at 20X magnification. Fig. 2N ; Supplementary Material, Fig. S1D ') within the cell cytoplasm, while exogenous FKRP (in red in Fig. 2N ; Supplementary Material, Fig. S1D '') was also found cytoplasmic but more localized nearby the cell nucleus. According to these results, for the in vivo experiments we infected FKRP L276I KI SCs with the optimal MOI 20 giving the higher transduction efficiency and the lower cell mortality.
In vitro release of wild type FKRP carrying-exosome (Fig. 4) confirmed the specificity of the wild type FKRP detection in the contralateral TAs. Since the FKRP-STEM antibody was not able to detect endogenous mutated FKRP (10, 14) , no bands were observed in the NI TAs (Fig. 4A ), while the not mutated form of C57Bl mouse was clearly detectable. Injected TAs muscles were also biochemically analysed for the recovery of a-DG glycosylation. The lowest dose of engineered-satellite cell injection didn't elicit a significant difference in a-DG glycosylation as compared to untreated muscles ( 
Exosomes-mediated systemic distribution of FKRP protein
In order to demonstrate the systemic trafficking of exosomes carrying FKRP prompted by the injection of transduced FKRP L276I KI SCs, plasma was collected from all the FKRP L276I KI injected mice, as well as from the not injected ones, for exosome isolation by SEC procedure. Unprocessed plasma and SEC elution plasma fractions were harvested and biochemically analysed. WB showed 60kDa FKRP corresponding bands for unprocessed plasma and plasma isolated exosomes from all the FKRP L276I KI The systemic effect of engineered-cell intramuscular transplantation was also evaluated by measuring the exogenous FKRP expression and a-DG glycosylation in the hearts of injected muscles. Heart muscles displayed a stronger positive signal as the number of injected cells increased from 35Â10 3 to 75Â10 3 , reaching a plateau between 75Â10 3 and 100Â10 3 injected mice. Similarly to WBs performed for TAs, the specificity of the FKRP band as wild type protein expression elicited by an exosomal source is ensured by the lack of detectable signal in the NI mouse hearts, while the positive control from C57Bl mouse heart showed a clear band corresponding to FKRP protein. As regards a-DG glycosylation, no pronounced differences were found among the three groups of injection, but an increased glycosylation was still observed taking in account the not injected mice and the positive control from C57Bl mouse ( Fig. 6D and E) .
In vitro modelling of dynamic FKRP carrying-exosome trafficking
In order to study the in vivo exosome trafficking dynamic, we reproduced an in vitro model mimicking the blood circulating FKRP shielded and transported within exosomes. Figure 7A shows Fig. 7E and F), mainly confined to cells that internalized exosomes (in red in Fig. 7E and F; Supplementary Material, Fig. S5B'' ). 
Muscle function analysis
FKRP L276I KI mice intramuscularly transplanted with engineered satellite cells were evaluated by two functional tests, treadmill and rotarod, which are commonly used to determine mice endurance. Treadmill results showed that mice did not receive cell transplant found extremely difficult to accomplish the test until the end of the experimental time points. In general, FKRP L276I KI mice seemed to become familiar with the treadmill after an initial training session (-T7) and are willing to run for the first week (T7), even though they maintained the running distance constantly below 400 meters and the running time around 1000 s. At T14, these mice became unable to sustain downhill treadmill running and showed extreme fatigue, implying an increased sensitivity to exercise-induced fatigue. mice showed an improvement trend ending up in performance comparable to the C57Bl mice at T7 and T14 (Fig. 8A-C) .
Discussion a-DG is a glycoprotein sited on muscle peripheral membranes (15, 16) , that undergoes glycosyltransferase-mediated N-glycosylation, mucin-type O-glycosylation, O-mannosylation, and an identified phosphorylated O-mannosyl glycan. While the loss of N-linked glycosylation on a-DG has no effects on its ability to bind extracellular ligands, defects in O-linked glycosylation result in a-DG hypoglycosylation and defective binding to laminin, neurexin, and agrin (17) , giving rise to congenital disorders named dystroglycanopathies. These latter features can also distinguish a family of muscular dystrophies with a wild clinical phenotype spectrum, ranging from congenital muscular (14), and the use of adeno-associated Virus 9 (AVV9)-FKRP that allows the systemic expression of fukutin related protein (10) . In line with these findings, we firstly isolated and infected MDC1C CD133þ blood-derived stem cells with lentiviral vector carrying the wild type form of human FKRP gene. FKRP-STEM antibody was used to specifically recognize the exogenous wild type FKRP from the endogenous mutated one (10) . This way, we demonstrated the restoration of exogenous isoform of FKRP protein expression in vitro. The lively interest in the novel role of FKRP as glycosyltransferase and the emerging idea of circulating glycosyltransferases (9) has brought out the hypothesis of a cell-mediated release of FKRP in vitro and in vivo (11) . In agreement with this expectation, it has been shown that fukutin, another glycosyltransferase responsible for Fukuyama muscular dystrophy, is secreted into culture media (18) . Furthermore, considering that the main route for glycosyltransferases to be transported to Golgi is protected and packaged into vesicles, we considered the involvement of exosomes as vesicles carrying FKRP. Exosomes are a homogeneous population of extracellular vesicles attracting particular attention for their ability to deliver cargos to cells in remote locations. In addition to genetic materials (19) and proteins, exosomes can be also enriched in post-translational modifier proteins, such as kinases, phosphatases, and glycosyltransferases, suggesting that FKRP can be effectively carried by exosomes released from transduced cells (20 Interestingly, unless previous studies localized FKRP expression in resident Golgi and endoplasmic reticulum, as punctuate dots in the cytoplasmic compartments of myofibers (3), we have detected FKRP positive signal at the sarcolemma level. This result is in line with previous studies showing a co-localization with a-DG (21) and suggesting that FKRP activity is required at sarcolemma for normal muscle function. Moreover, we observed two different types of staining: the first consisting in FKRPþ sarcolemma of cytoplasm GFP negative muscle fibers; the second seeing cytoplasm GFPþ fibers, together with the presence of perinuclear FKRPþ cells. These results would imply two different mechanisms of FKRP expression, one mediated by satellite cell fusion, and the other by exosome release. The staining against the glycosylated epitopes of a-DG showed a stronger positive sarcolemma signal in treated animals as the number of injected cells increased. These observations confirmed that the level of functionally glycosylated a-DG in the injected FKRP L276I KI Together, these data demonstrated that muscular dystrophies associated with a-DG glycosylation defects can be treated by a combined gene and cell therapy aimed at restoring FKRP expression and function. Exosomes carrying FKRP can also unexpectedly sustain these strategies, offering the possibility to achieve systemic and general outcomes and to boost the effect of an intramuscular injection.
Materials and Methods
Cell cultures
Isolation and FACS characterization of MDC1C blood-derived CD133þ stem cells. CD133þ blood-derived stem cells were isolated from a MDC1C patient affected by two heterozygous mutations in FKRP gene: c518T > G and c1087G > C, after obtaining related informed consent and according to Guidelines by the Committee on the Use of Human Subjects in Research at Policlinico Hospital of Milan. Blood sample was processed through a MACS magnetic column (Miltenyi Biotec; Bergisch Gladbach, Germany), as previously described (24 ing in the human mutation (nucleotide C826 to A) into the coding sequence of the mouse FKRP gene, resulting in amino acid replacement leucine 276 to isoleucine (L276I). Animals were housed in Charles River Laboratories (Calco, Italy) and provided with unlimited supply of drinking water and food. Briefly, hind limb muscles were washed in 1X phosphate-buffered saline (PBS: 8g/l NaCl, 0.2g/l KCl, 1.44g/l Na2HPO4, 0.24g/l KH2PO4 in distilled water; pH7.4) for blood cleansing. Muscles were placed in Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific; Waltham, Massachusetts, USA) with penicillin/streptomycin (100 ll/10ml) and fungizone (120 ll/10ml) for a manual connective and adipose tissue, blood vessel and nerve bundle removal under a dissection microscope. Subsequently, muscular tissue was mechanically homogenized and enzymatically digested for 30 min at 37 C with a solution of collagenase V (Sigma-Aldrich; St. Louis, Missouri, USA) 0.11 mg/ml, dispase (Gibco; Thermo Fisher Scientific; Waltham, Massachusetts, USA) 0.45 mg/ml, Dnase (Roche; Basilea, Switzerland) 0.01 mg/ml in 12 ml of Hank's balanced salt solution (HBSS). The mixture was filtered with a cell strainer (70mm), and incubated for 15 min. Cells were centrifuged at 458g for 20 min at RT. Finally, the pellet was suspended in DMEM at 20% of FBS with antibiotics, 1% embryonic extract chicken (CEE) (Gibco, Thermo Fisher Scientific; Waltham, Massachusetts, USA) and 2% horse serum (HS) (Gibco, Thermo Fisher Scientific; Waltham, Massachusetts, USA). Suspended cells were counted by Trypan blue (SigmaAldrich; St. Louis, Missouri, USA) and plated at a final density of 380 cellule/cm 2 in collagen-treated dishes at 37 C, 5% CO 2 .
Plates were incubated overnight and fresh medium was then replaced. SCs were phenotypically characterized by cytofluorimetric analysis, as already described. SCs were incubated with Pax7 (Hybridoma Bank; Lowa, USA) and CD29-FITC (Milteni Biotech; Bergisch Gladbach, Germany). For the first staining, SCs were fixed with 1.5% paraformaldehyde, followed by an overnight incubation with the primary antibody (dilution 1:10) at 4 C and by an incubation with monoclonal anti-mouse 488 Alexa
Fluor secondary antibody (Molecular Probe, Thermo Fisher Scientific; Waltham, Massachusetts, USA) (dilution 1:100). CD29 was detected incubating cells at 4 C for 20 min. Anti-7-alphaactin-mycin D (7-AAD) (Becton Dickinson, Immunocytometry Systems; San Diego, California, USA) staining was used to evaluate cell vitality. After staining, performed at 4 C for 20 min, cell suspensions were washed in PBS containing 1% heat inactivated FBS and 0.1% sodium azide. Cells were analysed using a FC500 cytomics flow cytometer (Beckman Coulter; Brea, California, USA) and 2.1 CXP software. Each analysis included at least 15,000-30,000 events. In vitro immunofluorescence staining (IF) was also performed to assess the SCs myogenic differentiation.
After reaching a confluence of 90%, the growing medium was replaced with DMEM 2% HS (differentiation medium), to induce SC myogenic differentiation in serum starvation conditions. Briefly, cells were fixed in formaldehyde 4% for 10 min at room temperature, and then incubated in blocking solution (5% of Titer of viral preparation. To establish the titer of viral preparation, 10 5 CD133þ blood derived stem cells were transduced with 5 Â 10 5 ip, 10 6 ip, 2 Â 10 6 ip in a 96-well plate (MOI of 5, 10, 20, respectively) immediately after cell isolation. Viral transduction was performed in 100 ll of DMEM supplemented with 10% FCS. 24-h post-transduction, fresh medium/well was added and cells were maintained at 37 C and 5% CO 2 . Each sample was evaluated in triplicate in three independent experiments. The transduction efficiency was evaluated after 6 days both by FACS -as % of GFP positive cells in 488 nm emission wavelengths -and by green fluorescence cell count through Fiji Analyse Particles function (Image J). Cells transduced with higher MOI 20 have been also examined for impaired viability due to undesirable virus cytotoxic effects. Trypan Blue Exclusion was performed every 5 days for 30 days on transduced and not transduced MDC1C CD133þ blood-derived stem cells, as previously described (27 (30) . Briefly, the 500 ml of concentrated supernatants were loaded on columns and elution was performed using PBS 1X as elution buffer. 0.5 ml fractions of the sample were collected. The protein concentration of each fraction was measured by microBCA Protein Assay Kit (Thermo Fisher Scientific; Waltham, Massachusetts, USA). Exosome characterization. To characterize exosomes by transmission electron microscopy (TEM) analysis, the pellet was resuspended in PBS 1X and 5ml were directly loaded onto formvarcarbon-coated grids. (31, 32) . The evaluation of vesicle absolute size distribution was performed using NanoSight LM10 (Malvern, UK). The NTA measurement conditions were settled: temperature 23.75 6 0. In vitro modelling of dynamic FKRP carrying-exosome trafficking. In order to mimic the FKRP trafficking within exosomes, a miniaturized, microfluidic bioreactor was employed and set up as described elsewhere with minor modifications (33) . The dynamic system is optically transparent and composed of three independent chambers, each hosting one independent polystyrene scaffold for cell culture (dimensions 6 Â 3 Â 0.4 mm, 3D Biotek; Hillsborough, NJ, USA). These scaffolds are composed of four layers of fibers (100 lm in diameter, with a pore size of 300 lm) shifted of 150 lm with respect to the adjacent (Fig. 4A) .
Three independent microfluidic channels, directly machined in the bioreactor body, perfuse the chambers. Scaffolds were pre-conditioned in sterile conditions with cell culture medium, as already described (34 For IF, serial TA muscle sections of 12 mm thickness were cut by cryostat (Leica CM1850). Staining of sections was performed for FKRP with rabbit anti FKRP-STEM antibody (diluted 1: 50), and mouse anti-GFP (dilution 1:500) (Abcam; Cambridge, UK). Tissue sections were also stained with mouse anti-Dystroglycan IIH6-C4-5 (1:50) (Hybridoma Bank; Lowa, USA), directed against glycan epitopes of a-DG. Monoclonal anti-rabbit 594, monoclonal antimouse 594 and monoclonal anti-mouse 488 (Molecular Probe; Thermo Fisher Scientific; Waltham, Massachusetts, USA) were added at a dilution of 1:100 for 1 h. Nuclei were stained with DAPI (Sigma-Aldrich; St. Louis, USA) and images were captured with Leica TCS SP2 confocal microscope. For WB analyses, Tas and HTs from all the FKRP L276I KI mice, injected and not injected, were homogenized in NP40 lysis buffer using a POTTER S Homogenizer (B. Braun Biotech International-Sartorius group; Melsungen, Germany). Sample were then incubated at 4 C for 15 min and finally centrifuged at 12000g for 15 min at 4 C. Total protein concentration was determined according to Lowry's method. 30 lg of each sample was loaded on 10% polyacrylamide gel for wild type FKRP detection (FKRP-STEM antibody, dilution 1:600), and on 8% polyacrylamide gel for a-DG detection (IIH6-C4-5, dilution 1:50) and transferred to nitrocellulose membranes (Bio-Rad; Hercules, California, USA Exosomes were isolated from the plasma using SEC device (qEV IZON Science; Scheafer, South East Europe) after diluting samples 1:2 with filtered PBS1X. According to the manufacturer's instructions, the first six eluted fractions are considered the "void volume" and discharged, while exosomes were predominantly found in fractions 7, 8, and 9. The last elution volumes, considered depleted from exosomes, were stored and analysed to determine the presence of free FKRP circulation not mediated by exosomes. The plasma exosome expression of wild type FKRP was evaluated throughout western blot analyses using anti FKRP-STEM antibody, as previously described for supernatant exosomes derived from MDC1C CD133þ blood-derived cells and FKRP L276I KI SCs. For FKRP detection of mouse plasma, 5ll of samples were directly mixed with Laemmli buffer and processed as already described. Functional measurements. Treadmill and Rotarod tests were performed on all the mice injected with 35 (n ¼ 4), 75 (n ¼ 5), and 100 (n ¼ 4) Â10 3 engineered FKRP L276I KI satellite cells for measuring the mice endurance. N ¼ 6 FKRP L276I KI not injected mice and n ¼ 5 age-matched C57Bl mice were used as controls. Four different time points were evaluated: 7 days before cell injection, the transplantation day (T0), and 7 and 14 days after (T7 and T14), after that the animals were sacrificed. Treadmill was conducted as a simple motor exercise as reported by (10) . Briefly, animals were placed on a motorized treadmill (Harvard Apparatus; Holliston, Massachusetts, USA) to run with an upward angle of 15 at a rate of 15m/min. In order to account for the high inter-individual variability, running meter outcomes from treated and untreated groups at T14 were also normalized to pre-exercise (7 days before the cell treatment) results for each FKRPL276I KI mouse, considered as "baseline level". The data for each group are now presented as percentage of averaged changes in running meters, calculated as [(Activity at T14/Activity 7days before the injections) Â 100] -100.The measurement was stopped when the mice spent 5 s blocked on the shock grid. Rotarod is a relatively complex motor training procedure, testing balance and coordination aspects of motor performance. Mice were placed on the rod that accelerated from 5 to 45 rotations/min within 15 s. When a mouse ran for 500 s without falling from the rod, the test session was ended. Mice that fell off within 500 s were given a maximum of two more tries. The longest running time was used for the analysis.
Statistical analysis
Prism 5.0 (Graphpad) statistical analysis was used. Statistical comparisons were based on Student's t-test or analysis of variance (ANOVA) with Tukey post-hoc test for pairwise comparisons. A confidence level of 95% was considered significant. Pvalues < 0.05 were considered significant.
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